S-488211

S-488211 is an investigational cancer peptide vaccine developed for the treatment of solid tumors, including non-muscle invasive bladder cancer. It is a freeze-dried injectable formulation containing two peptides—S-488204 (derived from DEPDC1) and S-488205 (derived from MPHOSPH1)—which are human leukocyte antigen (HLA)-A*02:01-restricted epitope peptides derived from cancer-testis antigens. These antigens are highly and differentially expressed in various solid tumors. The vaccine is designed to stimulate the immune system by presenting these tumor-associated antigens to antigen-presenting cells, leading to activation of cytotoxic T lymphocytes that target and destroy tumor cells[1][5]. S-488211 has been studied in combination with durvalumab, a PD-L1 inhibitor, in phase 1/2 clinical trials for non-muscle invasive bladder cancer[2][4][7].